Prevail Therapeutics (NASDAQ:PRVL) Downgraded to “Hold” at BidaskClub

Share on StockTwits

BidaskClub downgraded shares of Prevail Therapeutics (NASDAQ:PRVL) from a buy rating to a hold rating in a research report report published on Saturday morning, BidAskClub reports.

Several other analysts also recently weighed in on the company. Piper Sandler assumed coverage on Prevail Therapeutics in a research report on Thursday, April 9th. They set an overweight rating and a $20.00 price objective for the company. Citigroup assumed coverage on Prevail Therapeutics in a research report on Thursday, March 5th. They set a buy rating and a $24.00 price objective for the company. Wedbush upped their price objective on Prevail Therapeutics from $19.00 to $22.00 and gave the stock an outperform rating in a research report on Tuesday, May 26th. ValuEngine upgraded Prevail Therapeutics from a hold rating to a buy rating in a research report on Thursday, April 2nd. Finally, Zacks Investment Research downgraded Prevail Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, May 28th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Prevail Therapeutics currently has a consensus rating of Buy and an average target price of $20.00.

NASDAQ:PRVL opened at $14.90 on Friday. The stock has a fifty day moving average price of $16.36 and a 200-day moving average price of $15.76. The company has a market cap of $501.40 million and a price-to-earnings ratio of -6.51. The company has a debt-to-equity ratio of 0.06, a quick ratio of 14.32 and a current ratio of 14.32. Prevail Therapeutics has a fifty-two week low of $7.41 and a fifty-two week high of $19.96.

Prevail Therapeutics (NASDAQ:PRVL) last released its earnings results on Thursday, May 14th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Research analysts predict that Prevail Therapeutics will post -2.33 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its position in Prevail Therapeutics by 59.3% in the first quarter. BlackRock Inc. now owns 1,133,979 shares of the company’s stock valued at $13,823,000 after purchasing an additional 422,205 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Prevail Therapeutics in the fourth quarter valued at about $5,799,000. Bank of America Corp DE raised its position in Prevail Therapeutics by 15.3% in the fourth quarter. Bank of America Corp DE now owns 277,281 shares of the company’s stock valued at $4,389,000 after purchasing an additional 36,821 shares during the last quarter. Bank of New York Mellon Corp raised its position in Prevail Therapeutics by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 225,154 shares of the company’s stock valued at $2,745,000 after purchasing an additional 11,664 shares during the last quarter. Finally, State Street Corp raised its position in Prevail Therapeutics by 99.8% in the first quarter. State Street Corp now owns 209,515 shares of the company’s stock valued at $2,554,000 after purchasing an additional 104,629 shares during the last quarter. Hedge funds and other institutional investors own 80.50% of the company’s stock.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Story: What is Depreciation?

Analyst Recommendations for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.